Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus INNOHEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus INNOHEP.
ENOXAPARIN SODIUM vs INNOHEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Subcutaneous administration: 2500 IU anti-Xa (0.25 mL) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 mL) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
None Documented
None Documented
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin